Search results for "TC"

showing 10 items of 9993 documents

European reference values for the quality of life questionnaire EORTC QLQ-C30: Results of a German investigation and a summarizing analysis of six Eu…

2014

The aims of this study are to present the results of a new general population normative study of the quality of life questionnaire EORTC QLQ-C30 and to give European reference values averaged across six studies.The empirical study was based on a representative sample of the German adult population (N = 2448). The subjects were asked to fill in several questionnaires, one of them being the EORTC QLQ-C30.EORTC QLQ-C30 mean scores of this sample indicated slightly better quality of life (QoL) than in previous European studies. QoL decreased with age, but there were only small gender differences. The mean scores were compared with the age and gender adjusted scores of five other European normat…

AdultMalePediatricsmedicine.medical_specialtyAdolescentPopulationSample (statistics)European studiesGermanYoung AdultQuality of lifeReference ValuesGermanyNeoplasmsSurveys and QuestionnairesmedicineHumansRadiology Nuclear Medicine and imagingeducationAgedAged 80 and overeducation.field_of_studybusiness.industryEortc qlq c30social sciencesHematologyGeneral MedicineMiddle Agedhumanitieslanguage.human_languageEuropeOncologyReference valuesQuality of LifelanguageNormativeFemalebusinessDemographyActa Oncologica
researchProduct

Effects of age on depressive symptomatology and response to antidepressant treatment in patients with major depressive disorder aged 18 to 65 years

2020

Background: There is evidence that symptomatology in patients with major depressive disorder (MDD) changes with age. However, studies comparing depressive symptomatology between different age groups during antidepressant therapy are rare. We compared demographic and clinical characteristics in depressed patients of different age groups at baseline and during treatment. Methods: 889 MDD inpatients were divided into four age groups (18–29, 30–39, 40–49, 50–65 yrs.). Demographic and clinical characteristics including depressive symptomatology (assessed by the Inventory of Depressive Symptoms) were assessed at baseline and weekly during treatment. Results: At baseline, young patients (18–29 yea…

AdultMalePediatricsmedicine.medical_specialtyAdolescentlcsh:RC435-571IrritabilityDepressive symptomatology03 medical and health sciencesYoung Adult0302 clinical medicinelcsh:PsychiatrymedicineHumansIn patientDepression (differential diagnoses)AgedDepressive Disorder Majorbusiness.industryDepressionAge FactorsMiddle Agedmedicine.diseasePersonality disordersAntidepressive AgentsIrritable MoodSelf Concept030227 psychiatrySubstance abusePsychiatry and Mental healthClinical PsychologyTreatment OutcomeAntidepressantMajor depressive disorderFemalemedicine.symptombusiness030217 neurology & neurosurgeryComprehensive Psychiatry
researchProduct

Remission in schizophrenia — What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remissio…

2019

Despite being recommended for use in clinical trials, the consensus remission criteria were found to leave patients with persisting symptoms, relevant areas of functional impairment and a decreased sense of wellbeing. Therefore, to evaluate the appropriateness of the schizophrenia consensus criteria, a definition of remission based on the Clinical Global Impression Scale (CGI) was developed and remitter subgroups were compared.239 patients with a schizophrenia spectrum disorder were evaluated regarding their remission status after inpatient treatment. Remission in schizophrenia was defined according to the symptom-severity component of the consensus criteria by Andreasen et al. and a CGI ba…

AdultMalePediatricsmedicine.medical_specialtyConsensusMedizinConsensus criteriaSeverity of Illness IndexAsymptomaticYoung Adult03 medical and health sciences0302 clinical medicineRemission criteriaOutcome Assessment Health Caremental disordersmedicineHumansBiological PsychiatryDepression (differential diagnoses)Depressive Disorder Majorbusiness.industryRemission InductionMiddle Agedmedicine.disease030227 psychiatry3. Good healthClinical trialPsychiatry and Mental healthSchizophreniaSchizophreniaClinical Global ImpressionFemalemedicine.symptombusiness030217 neurology & neurosurgeryFollow-Up StudiesSchizophrenia spectrum
researchProduct

Factors associated with the quality of life of subjects with facial disfigurement due to surgical treatment of head and neck cancer

2018

Background Facial disfigurement has been considered one of the most challenging consequences of the surgical treatment for head and neck cancer patients, mainly due to the importance of the facial region for the personal identity, body self-image and interpersonal interactions, which might affect negatively the quality of life. The aim of this study was to assess factors associated with the quality of life of subjects with facial disfigurement due to surgical treatment. Material and Methods Clinical data were retrieved from 103 patient’s medical records and quality of life data were collected using the Functional Assessment of Cancer Therapy (FACT-H&N) questionnaire. Moreover, the degree of…

AdultMalePediatricsmedicine.medical_specialtyCross-sectional studyAffect (psychology)03 medical and health sciencesPostoperative Complications0302 clinical medicineQuality of lifeHumansMedicinePatient Reported Outcome MeasuresSurgical treatmentGeneral DentistryAgedAged 80 and overOral Medicine and Pathologybusiness.industryResearchMedical recordHead and neck cancer030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Disfigurementmedicine.diseaseCross-Sectional StudiesOtorhinolaryngologyHead and Neck NeoplasmsFace030220 oncology & carcinogenesisFacial disfigurementUNESCO::CIENCIAS MÉDICASQuality of LifeFemaleSurgerybusiness
researchProduct

Sequential treatment of ADHD in mother and child (AIMAC study): importance of the treatment phases for intervention success in a randomized trial

2018

Abstract Background The efficacy of parent-child training (PCT) regarding child symptoms may be reduced if the mother has attention-deficit/hyperactivity disorder (ADHD). The AIMAC study (ADHD in Mothers and Children) aimed to compensate for the deteriorating effect of parental psychopathology by treating the mother (Step 1) before the beginning of PCT (Step 2). This secondary analysis was particularly concerned with the additional effect of the Step 2 PCT on child symptoms after the Step 1 treatment. Methods The analysis included 143 mothers and children (aged 6–12 years) both diagnosed with ADHD. The study design was a two-stage, two-arm parallel group trial (Step 1 treatment group [TG]: …

AdultMalePediatricsmedicine.medical_specialtyEfficacylcsh:RC435-571610Motherslaw.inventionTreatment and control groups03 medical and health sciences0302 clinical medicinePharmacotherapy610 Medical sciences MedicineRandomized controlled trialChild of Impaired ParentslawIntervention (counseling)lcsh:PsychiatryMedicineHumans0501 psychology and cognitive sciencesddc:610ChildChildrenProblem BehaviorPsychiatric Status Rating ScalesPsychotropic Drugsbusiness.industryParent training05 social sciencesTreatment phasesAdult treatmentSequential treatmentCombined Modality Therapy3. Good healthPsychotherapyPsychiatry and Mental healthTreatment OutcomeAttention Deficit Disorder with HyperactivityParent trainingParental psychopathologyFemalebusiness030217 neurology & neurosurgery050104 developmental & child psychologyResearch Article
researchProduct

Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushing’s disease: interim results from a long-term real-world evidence st…

2019

Abstract Purpose Clinical trials have demonstrated the favorable efficacy/safety profile of pasireotide in patients with Cushing’s disease (CD). We report interim long-term results of an ongoing real-world evidence study of subcutaneous pasireotide in patients with CD. Methods Adults with CD receiving pasireotide, initiated before (prior-use) or at study entry (new-use), were monitored for ≤ 3 years during a multicenter observational study (http://clinicaltrials.gov identifier NCT02310269). Primary objective was to assess long-term safety of pasireotide alone or with other CD therapies. Results At the time of this interim analysis, 127 patients had received pasireotide (new-use, n = 31; pri…

AdultMalePediatricsmedicine.medical_specialtyEndocrinology Diabetes and MetabolismHypercortisolism030209 endocrinology & metabolismDiseaseArticleSettore MED/13 - Endocrinologia03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInterimmedicineHumansMulticenter Studies as TopicIn patientPituitary ACTH Hypersecretionbusiness.industryPituitary ACTH hypersecretionCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseasePasireotidePasireotideClinical trialTreatment OutcomePituitarychemistryHyperglycemiaFemaleLong term safetySafetySomatostatinbusiness030217 neurology & neurosurgeryPituitary
researchProduct

Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 cases

2013

Although it is still debated whether chronic cerebro-spinal venous insufficiency (CCSVI) plays a role in multiple sclerosis (MS) development, many patients underwent endovascular treatment (ET) of CCSVI. The objective of the study is to evaluate the outcome and safety of ET in Italian MS patients. Italian MS centers that are part of the Italian MS Study Group were all invited to participate to this retrospective study. A structured questionnaire was used to collect detailed clinical data before and after the ET. Data from 462 patients were collected in 33 centers. ET consisted of balloon dilatation (93 % of cases) or stent application. The mean follow-up duration after ET was 31 weeks. Mean…

AdultMalePediatricsmedicine.medical_specialtyMultiple Sclerosismedicine.medical_treatmentendovascular multiple sclerosis treatment venousDermatologyBalloon dilatationCohort StudiesSurveys and QuestionnairesMedicineHumansIn patientEndovascular treatmentAdverse effectBeneficial effectsbusiness.industryMultiple sclerosisEndovascular ProceduresStentBrainRetrospective cohort studyGeneral MedicineMiddle Agedmedicine.diseaseSurgeryPsychiatry and Mental healthTreatment OutcomeSpinal CordVenous InsufficiencySettore MED/26 - NeurologiaFemaleNeurology (clinical)businessMultiple sclerosis CCSVI Endovascular treatmentFollow-Up Studies
researchProduct

Latvian registry of familial hypercholesterolemia: The first report of three-year results.

2018

Abstract Background and aims Familial hypercholesterolemia (FH) was rarely diagnosed in Latvia before 2015, when the Latvian Registry of FH (LRFH) was established. Here, we report the first experience of the LRFH over three years (2015–2017). Methods The LRFH is an ongoing nationwide, dynamic, long-term prospective cohort. The diagnosis of FH was assessed using the Dutch Lipid Clinic Network (DLCN) criteria. Cascade screening of first-degree relatives using age- and sex-specific percentiles of low-density lipoprotein cholesterol (LDL-C) was performed in relatives of patients with definite and probable FH. Results Among the 416 individuals included in the LRFH, 181 patients were diagnosed wi…

AdultMalePediatricsmedicine.medical_specialtyStatinHeredityTime Factorsmedicine.drug_classDown-RegulationCascade screeningFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciences0302 clinical medicineRisk FactorsmedicineHumansGenetic Predisposition to Disease030212 general & internal medicineProspective StudiesRegistriesProspective cohort studyLipid clinicLipoprotein cholesterolAgedbusiness.industryAnticholesteremic AgentsMean ageCholesterol LDLMiddle Agedmedicine.diseaseLatviaCoronary heart diseasePedigreePhenotypeTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersAtherosclerosis
researchProduct

Migraine history and migraine-induced stroke in the Dijon stroke registry.

1999

Two thousand three hundred and eighty-nine patients with first-ever stroke were registered in the population-based Dijon Stroke Registry over an 11-year period. There was a history of migraine in 49 cases (2%), with a majority of women (2.8% versus 1.1% men) with the following distribution: 27 cases among 1,380 large-artery cerebral infarctions (1.9%), 6 cases among 358 small-artery cerebral infarctions (1.6%), 6 cases among 412 cerebral infarctions due to cardiac embolism (1.4%), 7 cases among 191 cerebral hemorrhages (3.6%) and 3 cases among 47 subarachnoid hemorrhages (6.3%). The male/female ratio was 0.58 for the 49 strokes with a history of migraine versus 1.27 for the 2,340 strokes wi…

AdultMalePediatricsmedicine.medical_specialtyStroke registryAdolescentEpidemiologyMigraine DisordersPopulationInfarctionCatchment Area HealthRecurrenceRisk FactorsEpidemiologyMedicineHumanscardiovascular diseasesProspective StudiesRegistrieseducationStrokeeducation.field_of_studybusiness.industryIncidence (epidemiology)Middle Agedmedicine.diseaseConfidence intervalCerebrovascular DisordersMigraineCommunity MedicineAnesthesiaPopulation SurveillanceFemaleNeurology (clinical)FrancebusinessNeuroepidemiology
researchProduct

Clinical and therapeutic features of myasthenia gravis in adults based on age at onset

2020

[Objective] To describe the characteristics of patients with very-late-onset myasthenia gravis (MG).

AdultMalePediatricsmedicine.medical_specialtyThymomagenetic structuresCross-sectional studyInvestigación médicaEnfermedad del sistema nerviosoMEDLINEMiastenia gravisLate onsetDISEASECLASSIFICATIONArticleACETYLCHOLINE-RECEPTOR03 medical and health sciences0302 clinical medicineimmune system diseasesMyasthenia GravismedicineEnfermedades neuromuscularesHumansRITUXIMAB030212 general & internal medicineAge of OnsetAgedbusiness.industryAnálisis de datosMiddle Agedmedicine.diseaseMyasthenia gravisnervous system diseasesCross-Sectional StudiesTreatment OutcomeMulticenter studyANTIBODIESAUTOANTIBODIESFemaleObservational studyNeurology (clinical)Age of onsetbusiness030217 neurology & neurosurgeryMUSK
researchProduct